Pms-topiramate weight loss
Monitor therapy CarBAMazepine: May decrease the serum concentration of Topiramate. Monitor anticonvulsant concentrations and treatment response closely with concurrent use. Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. It is not recommended to crush, break, or chew immediate release tablets due to bitter taste. Higher doses were not well tolerated (McElroy 2003). Additional data is necessary to further define the role of topiramate in this condition. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are taking the medication without consulting your doctor. If combined, limit the dosages and duration of each drug. It works by affecting chemicals in the brain that are involved in sending signals to nerves. Monitor therapy Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established. Monitor therapy Minocycline: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy Loop Diuretics: May enhance the hypokalemic effect of Topiramate. Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. Consider therapy modification HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. The medication and food should be swallowed immediately and not chewed. Consider therapy modification Contraceptives (Progestins): Topiramate may decrease the serum concentration of Contraceptives (Progestins). Topiramate belongs to a group of medications that are used to treat epilepsy. Consider therapy modification MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Avoid alcohol use with Trokendi XR capsules within 6 hours prior to and 6 hours after administration. Monitor therapy Contraceptives (Estrogens): Topiramate may decrease the serum concentration of Contraceptives (Estrogens). Monitor therapy Methenamine: Carbonic Anhydrase Inhibitors may diminish the therapeutic effect of Methenamine. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions. Avoid combination Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Topiramate may increase the serum concentration of Fosphenytoin. Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. These agents should only be combined if alternative treatment options are inadequate. Any use of alcohol with topiramate should be avoided when possible and should only be undertaken with extreme caution. Management: Consider dose reductions of droperidol or of other CNS agents (e. Alcohol (Ethyl) may increase the serum concentration of Topiramate. For epilepsy, topiramate can be used alone or in combination with other epilepsy medications. A single Qudexy XR dose with a high-fat meal delayed the T max by 4 hours. The sprinkle capsules can be swallowed whole or opened and sprinkled on a small amount (teaspoon) of soft food. Your doctor may have suggested this medication for conditions other than those listed in these drug information articles. If combined, limit the dosages and duration of each drug. Do not stop taking this medication without consulting your doctor. T max for Trokendi XR is shorter (16 hours). This applies specifically to use with the extended-release topiramate capsules (Trokendi XR). Topiramate is a medication that is used to treat epilepsy and to prevent migraine headaches. Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. Consider therapy modification Flecainide: Carbonic Anhydrase Inhibitors may increase the serum concentration of Flecainide. However, topiramate clearance in hepatic impairment may be reduced. Monitor therapy Lithium: Topiramate may increase the serum concentration of Lithium. Avoid combination Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. CrCl 2: Reduce dose to 50% of normal dose and titrate more slowly. Crush six 100 mg tablets in a mortar and reduce to a fine powder. Consider therapy modification Methotrimeprazine: May enhance the CNS depressant effect of CNS Depressants. Topiramate clearance is decreased only to the extent that renal function is reduced. Any specific brand name of this medication may not be available in all of the forms or approved for all of the conditions discussed here. Do not give this medication to anyone else, even if they have the same symptoms as you do.
[img][/img]
Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness. Monitor therapy HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone. Management: Monitor closely for evidence of excessive CNS depression. Consider therapy modification Cannabis: May enhance the CNS depressant effect of CNS Depressants. Swallow extended release (ER) and sprinkle capsules whole. Consider therapy modification Memantine: Carbonic Anhydrase Inhibitors may increase the serum concentration of Memantine. Do not sprinkle Trokendi XR capsules on food, chew, or crush. It can be harmful for people to take this medication if their doctor has not prescribed it. g. These agents should only be combined if alternative treatment options are inadequate. Topiramate may increase serum concentrations of the active metabolite(s) of Amitriptyline. Monitor therapy Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. , opioids, barbiturates) with concomitant use. Monitor therapy Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy Droperidol: May enhance the CNS depressant effect of CNS Depressants. Consider therapy modification Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants. Administer the immediate release formulation in divided doses. Stable for 90 days refrigerated (preferred) or at room temperature. Monitor therapy Mianserin: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Also, topiramate concentrations may be subtherapeutic in the later portion of the dosage interval. Nonmedicinal ingredients: colloidal silicon dioxide, copovidone, lactose, magnesium stearate, sodium starch glycolate, polyvinyl alcohol, titanium dioxide, macrogol, talc, and iron oxide yellow. All Consumer Professional Pill ID Interactions News FDA Alerts Approvals Pipeline Clinical Trials Care Notes Encyclopedia Dictionary Natural Products. For migraine prevention, topiramate is used to treat adults who have 4 or more migraine headaches a month and who have not responded to, or cannot take, medications that treat an acute migraine attack. Monitor therapy Mefloquine: May diminish the therapeutic effect of Anticonvulsants. The tablets can be taken with or without food. As well, some forms of this medication may not be used for all of the conditions discussed here. Monitor therapy Lofexidine: May enhance the CNS depressant effect of CNS Depressants. Topiramate may increase the serum concentration of Amitriptyline. Monitor therapy Dronabinol: May enhance the CNS depressant effect of CNS Depressants. Alcohol (Ethyl): May enhance the CNS depressant effect of Topiramate. Monitor therapy Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Monitor patients closely for the occurrence of kidney stones and with regards to severity of metabolic acidosis. Monitor therapy Amitriptyline: Topiramate may enhance the CNS depressant effect of Amitriptyline. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor. Monitor therapy Analgesics (Opioid): CNS Depressants may enhance the CNS depressant effect of Analgesics (Opioid). The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Plasma and renal clearance were reduced 21% and 19%, respectively. If you have not discussed this with your doctor or are not sure why you are taking this medication, speak to your doctor. CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Consider therapy modification Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Consider therapy modification Fosphenytoin: May decrease the serum concentration of Topiramate. Nahata MC, Pai VB, and Hipple TF, Pediatric Drug Formulations, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004. Management: Avoid concurrent use of different carbonic anhydrase inhibitors if possible. Monitor therapy Amphetamines: Carbonic Anhydrase Inhibitors may decrease the excretion of Amphetamines. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Management: Concurrent use of alcohol within 6 hours of ingestion of extended-release topiramate (Trokendi XR) is contraindicated. Increased intervals between dose adjustments may be considered. Bioequivalence has not been demonstrated between Trokendi XR and Qudexy XR.
